Longeveron Q2 2025 net loss $10M; HLHS trial fully enrolled, BLA filing targeted late 2026

Longeveron Inc.

2025-Q2 EPS reported -$0.67 vs consensus -$0.36 ▼ miss (-86.3%)

Revenue for H1 2025 $0.7M (-31% YoY); net loss $10.0M vs $7.5M in H1 2024.
ELPIS II Phase 2b trial for HLHS fully enrolled (40 patients); top-line results expected Q3 2026.
BLA submission for HLHS anticipated in late 2026 contingent on positive trial results.
FDA approved IND for pediatric dilated cardiomyopathy; Phase 2 trial expected H1 2026.
Cash $10.3M as of June 30; with $5M public offering, runway into Q1 2026; seeks additional financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.